

Ann K Daly

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5899205/ann-k-daly-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

301
papers

23,440
citations

79
h-index

147
g-index

324
ext. papers

26,235
ext. citations

8.3
avg, IF

6.72
L-index

#	Paper	IF	Citations
301	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance.. <i>JHEP Reports</i> , 2022 , 4, 100409	10.3	4
300	Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.. <i>JHEP Reports</i> , 2022 , 4, 100477	10.3	2
299	Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease.. <i>Journal of Hepatology</i> , 2021 ,	13.4	4
298	Obesity, Diabetes, Coffee, Tea, and Cannabis Use Alter Risk for Alcohol-Related Cirrhosis in 2 Large Cohorts of High-Risk Drinkers. <i>American Journal of Gastroenterology</i> , 2021 , 116, 106-115	0.7	7
297	Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensors. <i>Science Translational Medicine</i> , 2021 , 13, eabe8939	17.5	3
296	A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. <i>Journal of Hepatology</i> , 2021 ,	13.4	4
295	Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. <i>Nature Communications</i> , 2021 , 12, 6233	17.4	2
294	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021 , 592, 450-456	50.4	164
293	A Role in the Genetic Predisposition to NAFLD-HCC?. <i>Cancers</i> , 2021 , 13,	6.6	5
292	Pharmacogenomics spotlight commentary: From the United Kingdom to global populations. <i>British Journal of Clinical Pharmacology</i> , 2021 ,	3.8	1
291	Human Leukocyte Antigen B*14:01 and B*35:01 Are Associated With Trimethoprim-Sulfamethoxazole Induced Liver Injury. <i>Hepatology</i> , 2021 , 73, 268-281	11.2	19
290	PharmVar GeneFocus: CYP2C19. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 109, 352-366	6.1	27
289	Genetic Risk Factors in Drug-Induced Liver Injury Due to Isoniazid-Containing Antituberculosis Drug Regimens. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 109, 1125-1135	6.1	12
288	rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis. <i>Journal of Hepatology</i> , 2021 , 74, 20-30	13.4	24
287	Genome-wide Association Study and Meta-analysis on Alcohol-Associated Liver Cirrhosis Identifies Genetic Risk Factors. <i>Hepatology</i> , 2021 , 73, 1920-1931	11.2	18
286	PharmVar GeneFocus: CYP2C9. <i>Clinical Pharmacology and Therapeutics</i> , 2021 , 110, 662-676	6.1	7
285	Genetic Polymorphism of Drug-Metabolizing Enzymes and Drug Transporters in Drug Toxicity 2021 , 139-165		

284	Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis. <i>Hepatology</i> , 2021 , 74, 2452-2466	11.2	15
283	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2021 , 75, 770-785	13.4	19
282	HLA associations with infliximab-induced liver injury. <i>Pharmacogenomics Journal</i> , 2020 , 20, 681-686	3.5	8
281	Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2020 , 73, 252-262	13.4	65
280	Investigation of Oxidative Stress-Related Candidate Genes as Risk Factors for Drug-Induced Liver Injury due to Co-Amoxiclav. <i>DNA and Cell Biology</i> , 2020 , 39, 349-354	3.6	5
279	Pharmacogenomics of Drug-Induced Liver Injury. <i>Advances in Molecular Pathology</i> , 2020 , 3, 107-115	0.3	1
278	Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	51
277	HLA DRB1*15:01-DQB1*06:02-Restricted Human CD4+ T Cells Are Selectively Activated With Amoxicillin-Peptide Adducts. <i>Toxicological Sciences</i> , 2020 , 178, 115-126	4.4	10
276	Polygenic architecture informs potential vulnerability to drug-induced liver injury. <i>Nature Medicine</i> , 2020 , 26, 1541-1548	50.5	34
275	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. <i>Journal of Hepatology</i> , 2020 , 73, 505-515	13.4	113
274	Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 245-253	6.1	35
273	Endocytosis and Lack of Cytotoxicity of Alkyl-Capped Silicon Quantum Dots Prepared from Porous Silicon. <i>Materials</i> , 2019 , 12,	3.5	4
272	Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 1028-1036	6.1	34
271	Next-Generation Sequencing of Genes Reveals an Increased Frequency of Non-synonymous Variants Among Patients With NSAID-Induced Liver Injury. <i>Frontiers in Genetics</i> , 2019 , 10, 134	4.5	7
270	A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury. <i>Gastroenterology</i> , 2019 , 156, 1707-1716.e2	13.3	59
269	Genetic Polymorphisms Implicated in Nonalcoholic Liver Disease or Selected Other Disorders Have No Influence on Drug-Induced Liver Injury. <i>Hepatology Communications</i> , 2019 , 3, 1032-1035	6	4
268	Paracetamol metabolism, hepatotoxicity, biomarkers and therapeutic interventions: a perspective. <i>Toxicology Research</i> , 2018 , 7, 347-357	2.6	41
267	Human Leukocyte Antigen (HLA) and Other Genetic Risk Factors in Drug-Induced Liver Injury (DILI). <i>Methods in Pharmacology and Toxicology</i> , 2018 , 497-509	1.1	

266	Evaluation of laboratory tests for cirrhosis and for alcohol use, in the context of alcoholic cirrhosis. <i>Alcohol</i> , 2018 , 66, 1-7	2.7	8
265	Genetic and Clinical Factors Are Associated With Statin-Related Myotoxicity of Moderate Severity: A Case-Control Study. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 104, 178-187	6.1	13
264	Pharmacogenetics of Adverse Drug Reactions. <i>Advances in Pharmacology</i> , 2018 , 83, 155-190	5.7	23
263	Genetic risk factors for DILI-recent findings from large international networks. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018 , WCP2018, SY76-2	0	
262	HLA-A*33:03-Restricted Activation of Ticlopidine-Specific T-Cells from Human Donors. <i>Chemical Research in Toxicology</i> , 2018 , 31, 1022-1024	4	6
261	Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes. <i>Journal of Thrombosis and Haemostasis</i> , 2017 , 15, 465-472	15.4	7
260	Drug-Induced Cholestasis: Mechanisms and Importance 2017 , 117-128		
259	Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B*35:02 as a risk factor. <i>Journal of Hepatology</i> , 2017 , 67, 137-144	13.4	78
258	Are Polymorphisms in Genes Relevant to Drug Disposition Predictors of Susceptibility to Drug-Induced Liver Injury?. <i>Pharmaceutical Research</i> , 2017 , 34, 1564-1569	4.5	27
257	Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. <i>Gastroenterology</i> , 2017 , 152, 1078-1089	13.3	137
256	Age-stratified outcome of a genotype-guided dosing algorithm for acenocoumarol and phenprocoumon. <i>Journal of Thrombosis and Haemostasis</i> , 2017 , 15, 454-464	15.4	2
255	Pharmacogenetics: a general review on progress to date. <i>British Medical Bulletin</i> , 2017 , 124, 65-79	5.4	26
254	Pharmacogenomics of CYP2C9: Functional and Clinical Considerations. <i>Journal of Personalized Medicine</i> , 2017 , 8,	3.6	86
253	Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. <i>Cancer Medicine</i> , 2017 , 6, 1930-1940	4.8	29
252	Defining drug response for stratified medicine. <i>Drug Discovery Today</i> , 2017 , 22, 173-179	8.8	13
251	The Effect of the CYP1A1*2A Allele on Colorectal Cancer Susceptibility in a British Population. <i>Genetic Testing and Molecular Biomarkers</i> , 2016 , 20, 475-7	1.6	2
250	Variants in the LGALS9 Gene Are Associated With Development of Liver Disease in Heavy Consumers of Alcohol. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 762-8.e1	6.9	6
249	Weight Loss Decreases Excess Pancreatic Triacylglycerol Specifically in Type 2 Diabetes. <i>Diabetes Care</i> , 2016 , 39, 158-65	14.6	98

248	A multi-factorial analysis of response to warfarin in a UK prospective cohort. <i>Genome Medicine</i> , 2016 , 8, 2	14.4	32
247	Transcriptional regulation of PNPLA3 and its impact on susceptibility to nonalcoholic fatty liver Disease (NAFLD) in humans. <i>Aging</i> , 2016 , 9, 26-40	5.6	7
246	HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for flupirtine-induced liver injury. <i>Pharmacogenetics and Genomics</i> , 2016 , 26, 218-24	1.9	50
245	Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting. <i>Clinical Pharmacology and Therapeutics</i> , 2016 , 99, 172-85	6.1	100
244	Promiscuous T-cell responses to drugs and drug-haptens. <i>Journal of Allergy and Clinical Immunology</i> , 2015 , 136, 474-6.e8	11.5	31
243	Comparison of dosing algorithms for acenocoumarol and phenprocoumon using clinical factors with the standard care in the Netherlands. <i>Thrombosis Research</i> , 2015 , 136, 94-100	8.2	2
242	TM6SF2: catch-22 in the fight against nonalcoholic fatty liver disease and cardiovascular disease?. <i>Gastroenterology</i> , 2015 , 148, 679-84	13.3	58
241	Polymorphic Variants of Cytochrome P450: Relevance to Cancer and Other Diseases. <i>Advances in Pharmacology</i> , 2015 , 74, 85-111	5.7	29
240	Genetics of Alcoholic Liver Disease. <i>Seminars in Liver Disease</i> , 2015 , 35, 361-74	7.3	29
239	Brief report: genetics of alcoholic cirrhosis-GenomALC multinational study. <i>Alcoholism: Clinical and Experimental Research</i> , 2015 , 39, 836-42	3.7	22
238	Characterization of amoxicillin- and clavulanic acid-specific T cells in patients with amoxicillin-clavulanate-induced liver injury. <i>Hepatology</i> , 2015 , 62, 887-99	11.2	67
237	Quality of life in patients with venous thromboembolism and atrial fibrillation treated with coumarin anticoagulants. <i>Thrombosis Research</i> , 2015 , 136, 69-75	8.2	22
236	PNPLA3 Gene Polymorphism Is Associated With Predisposition to and Severity of Alcoholic Liver Disease. <i>American Journal of Gastroenterology</i> , 2015 , 110, 846-56	0.7	90
235	TM6SF2 as a genetic risk factor for fibrosis. <i>Hepatology</i> , 2015 , 62, 1321	11.2	2
234	Oral anticoagulation: a critique of recent advances and controversies. <i>Trends in Pharmacological Sciences</i> , 2015 , 36, 153-63	13.2	60
233	Pharmacogenetics of drug metabolizing enzymes in the United Kingdom population: review of current knowledge and comparison with selected European populations. <i>Drug Metabolism and Personalized Therapy</i> , 2015 , 30, 165-74	2	12
232	Patients benefit from genetics-guided coumarin anticoagulant therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2014 , 96, 15-7	6.1	13
231	Is there a need to teach pharmacogenetics?. <i>Clinical Pharmacology and Therapeutics</i> , 2014 , 95, 245-7	6.1	13

230	Identification of susceptible HLA class II co-amoxiclav genotypes based on the analysis of drug-specific T-cells from patients with liver injury. <i>Clinical and Translational Allergy</i> , 2014 , 4, O3	5.2	1
229	Characterization of amoxicillin and clavulanic-acid-responsive CD4+ And CD8+ T-cells in patients with co-amoxiclav-induced liver injury. <i>Clinical and Translational Allergy</i> , 2014 , 4, P42	5.2	78
228	N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group. <i>European Journal of Clinical Pharmacology</i> , 2014 , 70, 1079-86	2.8	48
227	TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. <i>Nature Communications</i> , 2014 , 5, 4309	17.4	362
226	Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014 , 61, 75-81	13.4	310
225	Point of care testing for improving risk- benefit ratio of aspirin and warfarin. <i>Molecular Cytogenetics</i> , 2014 , 7, 154	2	
224	Pharmacogenomics of Warfarin 2014 , 497-507		
223	Direct-to-consumer pharmacogenomic testing assessed in a US-based study. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2014 , 44, 212-3	0.9	
222	Gene polymorphisms of cellular senescence marker p21 and disease progression in non-alcohol-related fatty liver disease. <i>Cell Cycle</i> , 2014 , 13, 1489-94	4.7	44
221	Genetic basis of drug-induced liver injury: present and future. <i>Seminars in Liver Disease</i> , 2014 , 34, 123-33	7.3	95
220	Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon. <i>British Journal of Clinical Pharmacology</i> , 2014 , 77, 626-41	3.8	97
219	Human leukocyte antigen (HLA) pharmacogenomic tests: potential and pitfalls. <i>Current Drug Metabolism</i> , 2014 , 15, 196-201	3.5	17
218	Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms. <i>Archives of Toxicology</i> , 2013 , 87, 407-20	5.8	44
217	Relevance of CYP2E1 to non-alcoholic fatty liver disease. <i>Sub-Cellular Biochemistry</i> , 2013 , 67, 165-75	5.5	15
216	A randomized trial of genotype-guided dosing of warfarin. <i>New England Journal of Medicine</i> , 2013 , 369, 2294-303	59.2	617
215	Pharmacogenomics of adverse drug reactions. <i>Genome Medicine</i> , 2013 , 5, 5	14.4	72
214	Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser. <i>Journal of Clinical Virology</i> , 2013 , 58, 331-3	14.5	15
213	Genetic Predisposition to NAFLD and NASH: Implications for Pathogenesis, Diagnosis, Prevention, and Management 2013 , 157-170		

212 Genetic Factors in the Pathogenesis of Drug-Induced Liver Injury **2013**, 215-225

211 Lung cancer risk in relation to nicotinic acetylcholine receptor, CYP2A6 and CYP1A1 genotypes in the Bangladeshi population. *Clinica Chimica Acta*, **2013**, 416, 11-9 6.2 52

210 Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma. *Clinical Cancer Research*, **2013**, 19, 469-79 12.9 37

209 Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. *Hepatology*, **2013**, 57, 727-39 11.2 182

208 Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users. *Journal of Thrombosis and Haemostasis*, **2012**, 10, 606-14 15.4 19

207 An evaluation of gene-gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol. *Journal of Thrombosis and Haemostasis*, **2012**, 10, 767-72 15.4 14

206 Genetic polymorphisms affecting drug metabolism: recent advances and clinical aspects. *Advances in Pharmacology*, **2012**, 63, 137-67 5.7 22

205 Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs. *Pharmacogenomics*, **2012**, 13, 1405-17 2.6 15

204 The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies. *Journal of Hepatology*, **2012**, 56, 448-54 13.4 126

203 Pharmacogenetics: A Historical Perspective **2012**, 1-12

202 Pharmacogenetics in Drug Metabolism: Role of Phase I Enzymes **2012**, 13-80

201 Pharmacogenetics of Phase II Drug Metabolizing Enzymes **2012**, 81-100

200 Pharmacogenetics of Drug Transporters **2012**, 101-148 2

199 Pharmacogenetics of Drug Targets **2012**, 149-182

198 Pharmacogenetics in Cancer **2012**, 251-270

197 Cardiovascular Pharmacogenetics **2012**, 183-213

196 Pharmacogenetics in Psychiatry **2012**, 215-250

195 Pharmacogenetics of Asthma and COPD **2012**, 271-294

194	Pharmacogenetics of Adverse Drug Reactions 2012 , 295-321		1
193	Pharmacogenomics of Inflammatory Bowel Diseases 2012 , 323-351		
192	Pharmacogenetics of Pain Medication 2012 , 353-374		0
191	Ethical and Social Issues in Pharmacogenomics Testing 2012 , 375-400		
190	Developments in Analyses in Pharmacogenetic Datasets 2012 , 415-435		1
189	Applications of Pharmacogenetics in Pharmaceutical Research and Development 2012 , 437-460		
188	Role of Pharmacogenetics in Registration Processes 2012 , 461-475		1
187	Genetic association studies in drug-induced liver injury. <i>Drug Metabolism Reviews</i> , 2012 , 44, 116-26	7	79
186	VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children. <i>Blood</i> , 2012 , 119, 868-73	2.2	88
185	Using genome-wide association studies to identify genes important in serious adverse drug reactions. <i>Annual Review of Pharmacology and Toxicology</i> , 2012 , 52, 21-35	17.9	82
184	The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors. <i>British Journal of Clinical Pharmacology</i> , 2012 , 73, 66-76	3.8	57
183	CYP2D6 update: revised nomenclature for CYP2D7/2D6 hybrid genes. <i>Pharmacogenetics and Genomics</i> , 2012 , 22, 692-4	1.9	12
182	Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. <i>Pharmacogenetics and Genomics</i> , 2012 , 22, 784-95	1.9	96
181	High-Throughput Genotyping Technologies for Pharmacogenetics 2012 , 401-414		
180	Polymorphism in the farnesyl diphosphate farnesyl transferase 1 gene and nonalcoholic fatty liver disease severity. <i>Gastroenterology</i> , 2011 , 140, 1694-5	13.3	13
179	Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. <i>Gastroenterology</i> , 2011 , 141, 338-47	13.3	359
178	A Genome-Wide Association Study Identifies Potential Susceptibility Loci for Hepatotoxicity Due to Various Drugs. <i>Gastroenterology</i> , 2011 , 140, S-886	13.3	3
177	Genotypes and phenotypes of CYP3A in Bangladeshi population. <i>Clinica Chimica Acta</i> , 2011 , 412, 531-6	6.2	9

176	Genotyping for CYP2C9 and VKORC1 alleles by a novel point of care assay with HyBeacon [®] probes. <i>Clinica Chimica Acta</i> , 2011 , 412, 2063-9	6.2	28
175	Genetic modifiers of non-alcoholic fatty liver disease progression. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2011 , 1812, 1557-66	6.9	54
174	The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. <i>Journal of Hepatology</i> , 2011 , 55, 1409-14	13.4	65
173	Genetic determinants of susceptibility and severity in nonalcoholic fatty liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2011 , 5, 253-63	4.2	48
172	Family history of cancer and tobacco exposure in index cases of pancreatic ductal adenocarcinoma. <i>Journal of Oncology</i> , 2011 , 2011, 215985	4.5	10
171	Cyclooxygenase-2 polymorphisms and pancreatic cancer susceptibility. <i>Pancreas</i> , 2011 , 40, 1289-94	2.6	10
170	Characterization of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases. <i>British Journal of Pharmacology</i> , 2011 , 162, 989-99	8.6	9
169	The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions. <i>Clinical Pharmacology and Therapeutics</i> , 2011 , 89, 784-5	6.1	58
168	Case definition and phenotype standardization in drug-induced liver injury. <i>Clinical Pharmacology and Therapeutics</i> , 2011 , 89, 806-15	6.1	563
167	Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. <i>European Heart Journal</i> , 2011 , 32, 1909-17	9.5	78
166	Genetics of alcoholic and nonalcoholic fatty liver disease. <i>Seminars in Liver Disease</i> , 2011 , 31, 128-46	7.3	91
165	A common polymorphism in the ABCB11 gene is associated with advanced fibrosis in hepatitis C but not in non-alcoholic fatty liver disease. <i>Clinical Science</i> , 2011 , 120, 287-96	6.5	37
164	Clinical and pharmacogenetic influences on response to hydroxychloroquine in discoid lupus erythematosus: a retrospective cohort study. <i>Journal of Investigative Dermatology</i> , 2011 , 131, 1981-6	4.3	66
163	Genome-wide association studies in pharmacogenomics. <i>Nature Reviews Genetics</i> , 2010 , 11, 241-6	30.1	209
162	Role of UDP-glucuronosyltransferase isoforms in 13-cis retinoic acid metabolism in humans. <i>Drug Metabolism and Disposition</i> , 2010 , 38, 1211-7	4	12
161	Relevance of nonsynonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation. <i>Drug Metabolism and Disposition</i> , 2010 , 38, 1261-6	4	19
160	Polymorphisms in the tropomyosin TPM1 short isoform promoter alter gene expression and are associated with increased risk of metabolic syndrome. <i>American Journal of Hypertension</i> , 2010 , 23, 399-404	2.3	4
159	Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. <i>Gut</i> , 2010 , 59, 267-73	19.2	117

158	Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{ κ }B signalling pathways. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1315-20	2.4	59
157	Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. <i>Journal of Hepatology</i> , 2010 , 53, 1049-53	13.4	114
156	Pharmacogenetics and human genetic polymorphisms. <i>Biochemical Journal</i> , 2010 , 429, 435-49	3.8	78
155	Drug-induced liver injury: past, present and future. <i>Pharmacogenomics</i> , 2010 , 11, 607-11	2.6	65
154	Inter-individual variation in DNA damage and base excision repair in young, healthy non-smokers: effects of dietary supplementation and genotype. <i>British Journal of Nutrition</i> , 2010 , 103, 1585-93	3.6	35
153	A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives. <i>Pharmacogenomics</i> , 2010 , 11, 989-1002	2.6	19
152	A role for the pregnane X receptor in flucloxacillin-induced liver injury. <i>Hepatology</i> , 2010 , 51, 1656-64	11.2	50
151	Patatin-like phospholipase domain containing 3: a case in point linking genetic susceptibility for alcoholic and nonalcoholic liver disease. <i>Hepatology</i> , 2010 , 51, 1463-5	11.2	23
150	Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. <i>Hepatology</i> , 2010 , 51, 1209-17	11.2	445
149	Reversal of warfarin-induced over-anticoagulation with individualized dosing of oral vitamin K: a pilot study. <i>Journal of Thrombosis and Haemostasis</i> , 2010 , 8, 1123-5	15.4	5
148	Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. <i>Pharmacogenomics</i> , 2009 , 10, 1687-95	2.6	115
147	Genetic association studies in drug-induced liver injury. <i>Seminars in Liver Disease</i> , 2009 , 29, 400-11	7.3	87
146	Inter-individual variation in nucleotide excision repair in young adults: effects of age, adiposity, micronutrient supplementation and genotype. <i>British Journal of Nutrition</i> , 2009 , 101, 1316-23	3.6	30
145	HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. <i>Nature Genetics</i> , 2009 , 41, 816-9	36.3	818
144	Pharmacogenomics of anticoagulants: steps toward personal dosage. <i>Genome Medicine</i> , 2009 , 1, 10	14.4	27
143	Estimation of the warfarin dose with clinical and pharmacogenetic data. <i>New England Journal of Medicine</i> , 2009 , 360, 753-64	59.2	1161
142	Nomenclature for alleles of the cytochrome P450 oxidoreductase gene. <i>Pharmacogenetics and Genomics</i> , 2009 , 19, 565-6	1.9	26
141	Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study. <i>Pharmacogenetics and Genomics</i> , 2009 , 19, 800-12	1.9	49

140	Pharmacogenomics Applications in Drug Metabolism. <i>Methods in Pharmacology and Toxicology</i> , 2008 , 109-120	1.1	
139	Genetic susceptibility in pancreatic ductal adenocarcinoma. <i>British Journal of Surgery</i> , 2008 , 95, 22-32	5.3	15
138	Genetic variants of hepatic transporters and susceptibility to drug induced liver injury. <i>Toxicology</i> , 2008 , 253, 10	4.4	7
137	Relevance of PXR to Flucloxacillin-induced Liver Injury. <i>Toxicology</i> , 2008 , 253, 2	4.4	
136	Flucloxacillin-induced liver injury. <i>Toxicology</i> , 2008 , 254, 158-63	4.4	25
135	Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. <i>Gastroenterology</i> , 2007 , 132, 272-81	13.3	277
134	Factors affecting drug concentrations and QT interval during thioridazine therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2007 , 82, 555-65	6.1	26
133	Evidence that a polymorphism within the 3'RTR of glutathione peroxidase 4 is functional and is associated with susceptibility to colorectal cancer. <i>Genes and Nutrition</i> , 2007 , 2, 225-32	4.3	71
132	The Relationship between PON1 phenotype and PON1-192 genotype in detoxification of three oxons by human liver. <i>Drug Metabolism and Disposition</i> , 2007 , 35, 315-20	4	18
131	Individualized drug therapy. <i>Current Opinion in Drug Discovery & Development</i> , 2007 , 10, 29-36		9
130	Contribution of CYP2C9 to variability in vitamin K antagonist metabolism. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2006 , 2, 3-15	5.5	12
129	Significance of the minor cytochrome P450 3A isoforms. <i>Clinical Pharmacokinetics</i> , 2006 , 45, 13-31	6.2	170
128	APOE genotype makes a small contribution to warfarin dose requirements. <i>Pharmacogenetics and Genomics</i> , 2006 , 16, 609-11	1.9	42
127	A rapid genotyping method for the vitamin K epoxide reductase complex subunit 1 (VKORC1) gene. <i>Journal of Thrombosis and Haemostasis</i> , 2006 , 4, 1158-9	15.4	9
126	The impact of simvastatin on warfarin disposition and dose requirements. <i>Journal of Thrombosis and Haemostasis</i> , 2006 , 4, 1422-4	15.4	21
125	Genotyping for cytochrome P450 polymorphisms. <i>Methods in Molecular Biology</i> , 2006 , 320, 193-207	1.4	20
124	Pharmacogenetics of oral anticoagulants. <i>Personalized Medicine</i> , 2005 , 2, 23-27	2.2	2
123	Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. <i>Clinical Pharmacology and Therapeutics</i> , 2005 , 77, 468-78	6.1	287

122	Genetic polymorphism of manganese superoxide dismutase (MnSOD) and breast cancer susceptibility. <i>Cell Biochemistry and Function</i> , 2005 , 23, 73-6	4.2	32
121	Influence of IL-6, COL1A1, and VDR gene polymorphisms on bone mineral density in Crohn's disease. <i>Gut</i> , 2005 , 54, 1579-84	19.2	29
120	The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. <i>Blood</i> , 2005 , 106, 2329-33	2.2	799
119	Warfarin and celecoxib interaction in the setting of cytochrome P450 (CYP2C9) polymorphism with bleeding complication. <i>Postgraduate Medical Journal</i> , 2004 , 80, 107-9	2	27
118	N-acetyltransferase (NAT2) polymorphism and breast cancer susceptibility: a lack of association in a case-control study of Turkish population. <i>International Journal of Toxicology</i> , 2004 , 23, 25-31	2.4	17
117	CYP3A5 phenotype-genotype correlations in a British population. <i>British Journal of Clinical Pharmacology</i> , 2004 , 57, 664-664	3.8	78
116	Development of analytical technology in pharmacogenetic research. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2004 , 369, 133-40	3.4	11
115	Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. <i>Hepatology</i> , 2004 , 39, 1430-40	11.2	188
114	Association of metabolic gene polymorphisms with tobacco consumption in healthy controls. <i>International Journal of Cancer</i> , 2004 , 110, 266-70	7.5	20
113	Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 75, 204-12	6.1	162
112	CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. <i>Clinical Pharmacology and Therapeutics</i> , 2004 , 75, 422-33	6.1	150
111	Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. <i>Pharmacogenetics and Genomics</i> , 2004 , 14, 813-22		82
110	Pharmacogenetics of the cytochromes P450. <i>Current Topics in Medicinal Chemistry</i> , 2004 , 4, 1733-44	3	99
109	Altered tropomyosin expression in essential hypertension. <i>Hypertension</i> , 2003 , 41, 347-54	8.5	17
108	Genetic regulation of warfarin metabolism and response. <i>Seminars in Vascular Medicine</i> , 2003 , 3, 231-8		17
107	Pharmacogenetics of oral anticoagulants. <i>Pharmacogenetics and Genomics</i> , 2003 , 13, 247-52		156
106	Warfarin sensitivity: be aware of genetic influence. <i>Age and Ageing</i> , 2003 , 32, 226-7	3	6
105	Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. <i>Transplantation</i> , 2003 , 76, 1233-5	1.8	210

104	Genetic and epigenetic factors in autoimmune reactions toward cytochrome P4502E1 in alcoholic liver disease. <i>Hepatology</i> , 2003 , 37, 410-9	11.2	51
103	Do multiple cytochrome P450 isoforms contribute to parathion metabolism in man?. <i>Archives of Toxicology</i> , 2003 , 77, 313-20	5.8	32
102	Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. <i>Clinical Pharmacology and Therapeutics</i> , 2003 , 74, 380-7	6.1	136
101	Pharmacogenetics of the major polymorphic metabolizing enzymes. <i>Fundamental and Clinical Pharmacology</i> , 2003 , 17, 27-41	3.1	147
100	CYP3A5 phenotype-genotype correlations in a British population. <i>British Journal of Clinical Pharmacology</i> , 2003 , 55, 625-9	3.8	50
99	Candidate gene case-control studies. <i>Pharmacogenomics</i> , 2003 , 4, 127-39	2.6	20
98	Pharmacogenomics 2003 , 76-89		
97	CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. <i>Biochemical Pharmacology</i> , 2002 , 64, 1579-89	6	207
96	Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. <i>Neuropsychopharmacology</i> , 2002 , 27, 105-19	8.7	193
95	Valine-alanine manganese superoxide dismutase polymorphism is not associated with alcohol-induced oxidative stress or liver fibrosis. <i>Hepatology</i> , 2002 , 36, 1355-1360	11.2	39
94	Cytochrome P450 CYP1B1 and catechol O-methyltransferase (COMT) genetic polymorphisms and breast cancer susceptibility in a Turkish population. <i>Archives of Toxicology</i> , 2002 , 76, 643-9	5.8	71
93	CYP2C9 polymorphism and warfarin dose requirements. <i>British Journal of Clinical Pharmacology</i> , 2002 , 53, 408-9	3.8	19
92	CYP2D6 deficiency, a factor in ecstasy related deaths?. <i>British Journal of Clinical Pharmacology</i> , 2002 , 54, 69-70	3.8	31
91	Meta- and pooled analyses of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk. <i>Carcinogenesis</i> , 2002 , 23, 1343-50	4.6	228
90	Pooled analysis and meta-analysis of glutathione S-transferase M1 and bladder cancer: a HuGE review. <i>American Journal of Epidemiology</i> , 2002 , 156, 95-109	3.8	159
89	Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. <i>Pharmacogenetics and Genomics</i> , 2002 , 12, 121-32		268
88	Polymorphisms in immunoregulatory genes: towards individualized immunosuppressive therapy?. <i>Molecular Diagnosis and Therapy</i> , 2002 , 2, 13-23		15
87	Valine-alanine manganese superoxide dismutase polymorphism is not associated with alcohol-induced oxidative stress or liver fibrosis. <i>Hepatology</i> , 2002 , 36, 1355-60	11.2	13

86	Candidate gene case-control association studies: advantages and potential pitfalls. <i>British Journal of Clinical Pharmacology</i> , 2001 , 52, 489-99	3.8	118
85	Role of glutathione S-transferase P1, P-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance. <i>International Journal of Cancer</i> , 2001 , 92, 777-83	7.5	73
84	Role of polymorphisms in the interleukin-10 gene in determining disease susceptibility and phenotype in inflammatory bowel disease. <i>Digestive Diseases and Sciences</i> , 2001 , 46, 1520-5	4	39
83	Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. <i>Nature Genetics</i> , 2001 , 27, 383-91	36.3	1738
82	Association of single nucleotide polymorphisms in the interleukin-4 gene and interleukin-4 receptor gene with Crohn's disease in a British population. <i>Genes and Immunity</i> , 2001 , 2, 44-7	4.4	40
81	Pharmacogenetics of cytotoxic drugs. <i>Expert Review of Anticancer Therapy</i> , 2001 , 1, 301-8	3.5	1
80	The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. <i>Pharmacogenetics and Genomics</i> , 2001 , 11, 555-72		269
79	Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?. <i>Pharmacogenetics and Genomics</i> , 2001 , 11, 45-55		91
78	Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. <i>Pharmacogenetics and Genomics</i> , 2000 , 10, 511-8		96
77	Variation in induced CYP1A1 levels: relationship to CYP1A1, Ah receptor and GSTM1 polymorphisms. <i>Pharmacogenetics and Genomics</i> , 2000 , 10, 11-24		128
76	Human cytochrome P450 (CYP) genes: recommendations for the nomenclature of alleles. <i>Pharmacogenetics and Genomics</i> , 2000 , 10, 91-3		60
75	The effect of NAT2 genotype and gender on the metabolism of caffeine in nonsmoking subjects. <i>British Journal of Clinical Pharmacology</i> , 2000 , 49, 240-3	3.8	10
74	CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system. <i>British Journal of Clinical Pharmacology</i> , 2000 , 50, 77-80	3.8	24
73	Identification of human cytochrome P450 isoforms that contribute to all-trans-retinoic acid 4-hydroxylation. <i>Biochemical Pharmacology</i> , 2000 , 60, 517-26	6	127
72	Homozygosity for the Gly-9 variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients. <i>International Journal of Neuropsychopharmacology</i> , 2000 , 3, 61-65	5.8	35
71	Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. <i>Gut</i> , 2000 , 46, 540-5	19.2	125
70	Polymorphisms of the CYP2D6 gene increase susceptibility to ankylosing spondylitis. <i>Human Molecular Genetics</i> , 2000 , 9, 1563-6	5.6	59
69	Lung cancer risk in relation to genetic polymorphisms of microsomal epoxide hydrolase among African-Americans and Caucasians in Los Angeles County. <i>Lung Cancer</i> , 2000 , 28, 147-55	5.9	62

68	CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2000 , 32, 538-41	13.4	157
67	Warfarin dose requirement and CYP2C9 polymorphisms. <i>Lancet, The</i> , 1999 , 353, 1972-1973	40	17
66	Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. <i>Lancet, The</i> , 1999 , 353, 717-9	40	1066
65	Genetic variation of CYP2A6, smoking, and risk of cancer. <i>Lancet, The</i> , 1999 , 353, 898-9	40	126
64	Tumour necrosis factor-alpha promoter polymorphisms in primary biliary cirrhosis. <i>Journal of Hepatology</i> , 1999 , 30, 232-6	13.4	70
63	Genetic epidemiology of environmental toxicity and cancer susceptibility: human allelic polymorphisms in drug-metabolizing enzyme genes, their functional importance, and nomenclature issues. <i>Drug Metabolism Reviews</i> , 1999 , 31, 467-87	7	83
62	Low frequency of CYP2A6 gene polymorphism as revealed by a one-step polymerase chain reaction method. <i>Pharmacogenetics and Genomics</i> , 1999 , 9, 327-32		41
61	Detailed modelling of caffeine metabolism and examination of the CYP1A2 gene: lack of a polymorphism in CYP1A2 in Caucasians. <i>Pharmacogenetics and Genomics</i> , 1999 , 9, 367-75		45
60	CYP2D6 is associated with Parkinson's disease but not with dementia with Lewy Bodies or Alzheimer's disease. <i>Pharmacogenetics and Genomics</i> , 1999 , 9, 31-5		43
59	Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. <i>Hepatology</i> , 1998 , 27, 1695-9	11.2	173
58	Tumour necrosis factor-alpha gene promoter polymorphism and decreased insulin resistance. <i>Diabetologia</i> , 1998 , 41, 430-4	10.3	102
57	No evidence for involvement of the interleukin-10 -592 promoter polymorphism in genetic susceptibility to primary biliary cirrhosis. <i>Journal of Hepatology</i> , 1998 , 28, 820-3	13.4	30
56	Recent advances in understanding the molecular basis of polymorphisms in genes encoding cytochrome P450 enzymes. <i>Toxicology Letters</i> , 1998 , 102-103, 143-7	4.4	45
55	Heterozygotes for HFE mutations have no increased risk of advanced alcoholic liver disease. <i>Gut</i> , 1998 , 43, 262-6	19.2	74
54	Analysis of cytochrome P450 polymorphisms. <i>Methods in Molecular Biology</i> , 1998 , 107, 405-22	1.4	10
53	The RsaI polymorphism of CYP2E1 and susceptibility to alcoholic liver disease in Caucasians: effect on age of presentation and dependence on alcohol dehydrogenase genotype. <i>Pharmacogenetics and Genomics</i> , 1998 , 8, 335-42		84
52	An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. <i>Pharmacogenetics and Genomics</i> , 1998 , 8, 129-35		88
51	CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. <i>Pharmacogenetics and Genomics</i> , 1998 , 8, 529-41		99

50	Detection and characterization of novel polymorphisms in the CYP2E1 gene. <i>Pharmacogenetics and Genomics</i> , 1998 , 8, 543-52		93
49	Relationship between acetylator status, smoking, and diet and colorectal cancer risk in the north-east of England. <i>Carcinogenesis</i> , 1997 , 18, 1351-4	4.6	93
48	CYP2E1 genetic polymorphisms and risk of nasopharyngeal carcinoma in Taiwan. <i>Journal of the National Cancer Institute</i> , 1997 , 89, 1207-12	9.7	162
47	Genetic polymorphism of CYP2D6 and lung cancer risk in African-Americans and Caucasians in Los Angeles County. <i>Carcinogenesis</i> , 1997 , 18, 1203-14	4.6	52
46	Characterization of the 16+9 kb and 30+9 kb CYP2D6 XbaI haplotypes. <i>Pharmacogenetics and Genomics</i> , 1997 , 7, 149-52		14
45	Lung cancer risk in relation to the CYP2C9 genetic polymorphism among Caucasians in Los Angeles County. <i>Pharmacogenetics and Genomics</i> , 1997 , 7, 401-4		30
44	Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype. <i>British Journal of Psychiatry</i> , 1997 , 170, 23-6	5.4	86
43	Presenilin polymorphisms in Alzheimer's disease. <i>Lancet, The</i> , 1997 , 350, 958-9	4.0	11
42	Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. <i>Hepatology</i> , 1997 , 26, 143-6	11.2	279
41	Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. <i>FEBS Letters</i> , 1996 , 392, 30-4	3.8	159
40	CYP2D6 multiallelism. <i>Methods in Enzymology</i> , 1996 , 272, 199-210	1.7	109
39	Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California. <i>Pharmacogenetics and Genomics</i> , 1996 , 6, 527-33		62
38	Lung cancer risk in relation to the CYP2E1 Rsa I genetic polymorphism among African-Americans and Caucasians in Los Angeles County. <i>Pharmacogenetics and Genomics</i> , 1996 , 6, 151-8		45
37	Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype. <i>Pharmacogenetics and Genomics</i> , 1996 , 6, 319-28		47
36	Nomenclature for human CYP2D6 alleles. <i>Pharmacogenetics and Genomics</i> , 1996 , 6, 193-201		348
35	Stereoselective cardiotoxic effects of terodiline. <i>Clinical Pharmacology and Therapeutics</i> , 1996 , 60, 89-98.1		34
34	Relationship between genotype for the cytochrome P450 CYP2D6 and susceptibility to ankylosing spondylitis and rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 1996 , 55, 66-8	2.4	41
33	Molecular basis of polymorphic drug metabolism. <i>Journal of Molecular Medicine</i> , 1995 , 73, 539-53	5.5	71

32	An inactive cytochrome P450 CYP2D6 allele containing a deletion and a base substitution. <i>Human Genetics</i> , 1995 , 95, 337-41	6.3	28
31	Polymorphism of glutathione S-transferase M1 and lung cancer risk among African-Americans and Caucasians in Los Angeles County, California. <i>Journal of the National Cancer Institute</i> , 1995 , 87, 1246-53	9.7	103
30	Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. <i>Pharmacogenetics and Genomics</i> , 1995 , 5, 215-23		230
29	Comparison of substrate metabolism by wild type CYP2D6 protein and a variant containing methionine, not valine, at position 374. <i>Pharmacogenetics and Genomics</i> , 1995 , 5, 234-43		32
28	Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. <i>Biochemical Pharmacology</i> , 1994 , 47, 1157-63	6	101
27	Poor metabolisers of nicotine and CYP2D6 polymorphism. <i>Lancet, The</i> , 1994 , 343, 62-3	40	50
26	Genotyping of the CYP 2D6 gene in Norwegian lung cancer patients and controls. <i>Pharmacogenetics and Genomics</i> , 1994 , 4, 47-57		19
25	Debrisoquine 4-hydroxylation (CYP2D6) polymorphism in Jordanians. <i>Pharmacogenetics and Genomics</i> , 1994 , 4, 159-61		8
24	The cytochrome P450 CYP2D6 allelic variant CYP2D6J and related polymorphisms in a European population. <i>Pharmacogenetics and Genomics</i> , 1994 , 4, 73-81		47
23	New Opportunities in Cancer Risk Evaluation Using PCR-Based DNA Analysis for CYP2D6. <i>Environmental Health Perspectives</i> , 1993 , 101, 117	8.4	1
22	A polymorphic Cfol site in exon 6 of the human cytochrome P450 CYP2D6 gene detected by the polymerase chain reaction. <i>Human Genetics</i> , 1993 , 91, 616-7	6.3	16
21	Metabolic polymorphisms 1993 , 57, 129-60		159
20	Deficient nifedipine oxidation: a rare inherited trait associated with cystic fibrosis kindreds. <i>Pharmacogenetics and Genomics</i> , 1992 , 2, 19-24		16
19	The pharmacogenetics of chemical carcinogenesis. <i>Pharmacogenetics and Genomics</i> , 1992 , 2, 246-58		52
18	Mutant debrisoquine hydroxylation genes in Parkinson's disease. <i>Lancet, The</i> , 1992 , 339, 1017-8	40	221
17	The role of individual human cytochromes P450 in drug metabolism and clinical response. <i>Trends in Pharmacological Sciences</i> , 1992 , 13, 434-9	13.2	202
16	Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes. <i>Pharmacogenetics and Genomics</i> , 1991 , 1, 33-41		98
15	Identification and analysis of retinoic acid-binding proteins and receptors from nuclei of mammalian cells. <i>Methods in Enzymology</i> , 1990 , 189, 239-47	1.7	11

14	Cellular retinoic acid-binding protein from neonatal rat skin: purification and analysis. <i>Methods in Enzymology</i> , 1990 , 189, 307-14	1.7	
13	Molecular genotyping to predict debrisoquine hydroxylation phenotype. <i>Lancet, The</i> , 1990 , 336, 889-90	4.0	5
12	The biological activity of retinoids in melanoma cells. Induction of expression of retinoic acid receptor-beta by retinoic acid in S91 melanoma cells. <i>FEBS Letters</i> , 1990 , 273, 19-22	3.8	22
11	Nuclear retinoic-acid-binding proteins and receptors in retinoic-acid-responsive cell lines. <i>Pathobiology</i> , 1989 , 57, 339-45	3.6	1
10	Purification and properties of cellular retinoic acid-binding protein from neonatal rat skin. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1988 , 965, 118-26	4	12
9	Characterisation of a retinoic-acid-binding component from F9 embryonal-carcinoma-cell nuclei. <i>FEBS Journal</i> , 1987 , 168, 133-9		33
8	Kinetic studies on the major form of aldehyde reductase in ox kidney: a general kinetic mechanism to explain substrate-dependent mechanisms and the inhibition by anticonvulsants. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 1986 , 1, 163-8		7
7	Interphase nuclear matrix and metaphase scaffolding structures. <i>Journal of Cell Science</i> , 1984 , 1, 103-22	5.3	70
6	The kinetic mechanism of the major form of ox kidney aldehyde reductase with D-glucuronic acid. <i>Biochemical Journal</i> , 1982 , 205, 381-8	3.8	15
5	Nash is A Genetically Determined Disease66-75		
4	Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease		1
3	Pharmacogenetics: Possibilities and Pitfalls477-483		
2	A trans-ancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation		5
1	A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation. <i>Nature Genetics</i> ,	36.3	2